Back to Search Start Over

Epilepsy phenotype and response to KCNQ openers in mice harboring the Kcnq2 R207W voltage-sensor mutation.

Authors :
Tian F
Cao B
Xu H
Zhan L
Nan F
Li N
Taglialatela M
Gao Z
Source :
Neurobiology of disease [Neurobiol Dis] 2022 Nov; Vol. 174, pp. 105860. Date of Electronic Publication: 2022 Sep 14.
Publication Year :
2022

Abstract

KCNQ2-encoded Kv7.2 subunits play a critical role in balancing neuronal excitability. Mutations in KCNQ2 are responsible for highly-heterogenous epileptic and neurodevelopmental phenotypes ranging from self-limited familial neonatal epilepsy (SeLFNE) to severe developmental and epileptic encephalopathy (DEE). Pathogenic KCNQ2 variants cluster at the voltage sensor domain (VSD), the pore domain, and the C-terminal tail. Although several knock-in mice harboring Kcnq2 pore variants have been developed, no mouse line carrying Kcnq2 voltage-sensor mutations has been described. KCNQ2-R207W is an epilepsy-causing mutation located in the VSD, mainly affecting voltage-dependent channel gating. To study the physiological consequence of Kcnq2 VSD dysfunction, we generated a Kcnq2-R207W mouse line and analyzed the pathological and pharmacological phenotypes of mutant mice. As a result, both homozygous (Kcnq2 <superscript>RW/RW</superscript> ) and heterozygous (Kcnq2 <superscript>RW/+</superscript> ) mice were viable. While Kcnq2 <superscript>RW/RW</superscript> mice displayed a short lifespan, growth retardation, and spontaneous seizures, Kcnq2 <superscript>RW/+</superscript> mice survived and developed normally, although only a fraction (9/64; 14%) of them showed behavioral- and ECoG-confirmed spontaneous seizures. Kcnq2 <superscript>RW/+</superscript> mice displayed increased susceptibility to evoked seizures, which was dramatically ameliorated by treatment with the novel KCNQ opener pynegabine (HN37). Our results show that the Kcnq2-R207W mouse line, the first harboring a Kcnq2 voltage-sensor mutation, exhibits a unique epileptic phenotype with both spontaneous seizures and increased susceptibility to evoked seizures. In Kcnq2-R207W mice, the potent KCNQ opener HN37, currently in clinical phase I, shows strong anticonvulsant activity, suggesting it may represent a valuable option for the severe phenotypes of KCNQ2-related epilepsy.<br /> (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1095-953X
Volume :
174
Database :
MEDLINE
Journal :
Neurobiology of disease
Publication Type :
Academic Journal
Accession number :
36113748
Full Text :
https://doi.org/10.1016/j.nbd.2022.105860